Modeling serum M‐protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasone

Abstract Multiple myeloma (MM) treatment guidelines recommend waiting for formal progression criteria (FPC) to be met before proceeding to the next line of therapy. As predicting progression may allow early switching to next‐line therapy while the disease burden is relatively low, we evaluated the p...

Full description

Bibliographic Details
Main Authors: Yuki Otani, Yunqi Zhao, Guanyu Wang, Richard Labotka, Mark Rogge, Neeraj Gupta, Majid Vakilynejad, Dean Bottino, Yusuke Tanigawara
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.13225